Wegovy and Ozempic contain the same active ingredient, semaglutide, made by the same manufacturer. The difference isn’t the drug itself but what it’s approved for, the doses available, and how insurance treats each one. Which is “better” depends entirely on whether your primary goal is weight loss, blood sugar control, or both.
Same Drug, Different Labels
Semaglutide works by mimicking a hormone your gut naturally produces after eating. It signals your brain to feel full sooner, slows the rate your stomach empties, and helps your pancreas release insulin more effectively when blood sugar rises. Both Wegovy and Ozempic deliver this same compound through a once-weekly injection.
The FDA approved Ozempic specifically for type 2 diabetes management and cardiovascular risk reduction in people with diabetes. Wegovy is approved for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related health condition. In early 2026, the FDA also approved Wegovy HD, a higher 7.2 mg dose, for adults who need additional weight loss beyond what the standard dose provides.
Dosing Differences Matter
Ozempic tops out at 2.0 mg per week. Wegovy’s standard maintenance dose is 2.4 mg per week, and the newer Wegovy HD goes up to 7.2 mg. That higher ceiling is significant: more semaglutide generally means more weight loss and appetite suppression.
Both medications require a gradual dose increase over several weeks to reduce side effects. With Ozempic, you typically start at 0.25 mg and step up to 0.5 mg, then 1.0 mg, with 2.0 mg as the maximum. Wegovy follows a similar ramp but continues upward to 1.7 mg and then 2.4 mg for maintenance. If you’re switching from Ozempic 1.0 mg to Wegovy, you’d continue at 1.0 mg for four weeks, move to 1.7 mg for four weeks, then settle at 2.4 mg. The first Wegovy dose is given seven days after your last Ozempic injection.
Weight Loss: Wegovy Has the Edge
Because Wegovy reaches higher doses, it produces more weight loss. In the SUSTAIN FORTE trial comparing Ozempic’s two dose levels, participants on 2.0 mg lost an average of 6.9 kg (about 15 pounds) over 40 weeks, while those on 1.0 mg lost 6.0 kg. Clinical trials for Wegovy at 2.4 mg have consistently shown greater reductions, and the new 7.2 mg dose pushes results further still. For people whose primary goal is losing weight, Wegovy is the stronger option on paper.
That said, many people prescribed Ozempic for diabetes also lose a meaningful amount of weight. If you have type 2 diabetes and need to manage blood sugar, Ozempic may accomplish both goals at once, even if the weight loss is somewhat less dramatic than what Wegovy can deliver.
Blood Sugar Control
Ozempic was designed and studied as a diabetes medication. Its clinical trial program focused on lowering A1c levels and improving blood sugar stability. If you have type 2 diabetes, Ozempic is the straightforward choice because it carries the FDA indication for that condition and insurers cover it accordingly.
Wegovy also lowers blood sugar. The FDA noted that the higher-dose Wegovy HD provided similar A1c reductions compared to the standard dose in people with both obesity and type 2 diabetes. But Wegovy’s label is built around weight management, not diabetes treatment. If diabetes control is your priority, your doctor will likely start with Ozempic (or keep you on it) because the regulatory and insurance pathways are cleaner.
Heart Health Benefits
Semaglutide at Wegovy-level doses has shown significant cardiovascular benefits. The SELECT trial found that semaglutide reduced major cardiovascular events (heart attack, stroke, or cardiovascular death) by roughly 28% compared to placebo in people with obesity and existing heart disease. Among participants who also had heart failure, the benefit held strong regardless of the type of heart failure they had. These findings led to Wegovy gaining an additional FDA indication for cardiovascular risk reduction in people with obesity.
Ozempic also carries an indication for reducing cardiovascular risk, but specifically in adults with type 2 diabetes and established heart disease. If you don’t have diabetes but do have obesity and cardiovascular concerns, Wegovy is the version with the matching approval.
Cost and Insurance Coverage
This is often the deciding factor. Following price cuts by Novo Nordisk, the Wegovy injectable pen costs about $349 per month, with a discounted $199 price for new patients during the first two months. Ozempic runs between $349 and $499 per month depending on dose, with the same $199 introductory offer for new self-pay patients. Wegovy is also available in pill form through direct-to-consumer channels at $149 to $299 per month depending on dosage.
Insurance coverage differs sharply between the two. Ozempic is covered by most plans as a diabetes medication, so if you have a type 2 diabetes diagnosis, getting it approved is relatively straightforward. Wegovy coverage for weight management is more variable. Many private insurers now cover it, but they typically require documentation of a BMI at or above 30 (or 27 with a related condition like high blood pressure or sleep apnea). Medicare began covering anti-obesity medications more recently, but access still varies by plan. Some people find it easier to get Ozempic covered even when their real motivation is weight loss, though using it off-label for that purpose can create its own insurance headaches.
Side Effects Are Essentially the Same
Because the active ingredient is identical, the side effect profile overlaps almost completely. Nausea is the most common complaint, especially during dose increases, along with vomiting, diarrhea, constipation, and stomach pain. These symptoms tend to improve after the first few weeks at each new dose level, which is why the gradual titration schedule exists.
The higher doses available with Wegovy may produce more intense GI side effects for some people, particularly at the 2.4 mg dose and above. Starting low and increasing slowly helps, but if you’re especially sensitive, the lower ceiling of Ozempic could actually be an advantage, even if it means slightly less weight loss.
Which One Should You Choose
The decision comes down to your diagnosis and your goals. If you have type 2 diabetes, Ozempic is the natural starting point. It’s FDA-approved for your condition, insurance covers it with less friction, and you’ll likely lose some weight as a secondary benefit. If your A1c is well-controlled but you need more weight loss, switching to Wegovy and its higher doses is a logical next step.
If you don’t have diabetes and your primary concern is weight loss or cardiovascular risk tied to obesity, Wegovy is the purpose-built option. It offers higher doses, carries the right FDA indications, and has the clinical data from the SELECT trial backing its cardiovascular benefits in people without diabetes. The tradeoff is that insurance approval can take more effort, and out-of-pocket costs may be higher depending on your plan.
Neither drug is objectively “better.” They’re the same molecule aimed at different problems. The best choice is the one that matches your health situation and that you can actually access and afford consistently, because semaglutide only works for as long as you take it.